Estrogen is an important component for the sustenance of normal physiological functions of the mammary glands, particularly for growth and differentiation. Approximately, two-thirds of breast cancers are positive for estrogen receptor (ERs), which is a predisposing factor for the growth of breast cancer cells. As such, ERa represents a lucrative therapeutic target for breast cancer that has attracted wide interest in the search for inhibitory agents. However, the conventional laboratory processes are cost-and time-consuming. Thus, it is highly desirable to develop alternative methods such as quantitative structure-activity relationship (QSAR) models for predicting ER-mediated endocrine agitation as to simplify their prioritization for future screening. In this study, we compiled and curated a large, non-redundant data set of 1231 compounds with ERa inhibitory activity (pIC 50 ). Using comprehensive validation tests, it was clearly observed that the model utilizing the substructure count as descriptors, performed well considering two objectives: using less descriptors for model development and achieving high predictive performance (R Tr 2 ¼ 0.94, Q CV 2 ¼ 0.73, and Q Ext 2 ¼ 0.73). It is anticipated that our proposed QSAR model may become a useful highthroughput tool for identifying novel inhibitors against ERa.
Introduction
Breast cancer is a serious public health concern worldwide 1 with 14.1 million new cancer cases, 2 accounting for an estimated death of 8.8 million in 2015. 3 The global burden of breast cancer has increased as more than 1.7 million women are annually diagnosed with breast cancer. 4 Out of all the cases, two-thirds of breast cancers are estrogen receptor (ERs) positive whereby the cancer cells consisting of ERs, when bound to estrogen, are signalled to proliferate. 5 The metabolism of estrogen results in increased oxidative stress along with the production of genotoxic metabolites that form DNA adducts thereby causing genomic instability and eventually leading to the initiation of cancer.
ER belongs to the steroid nuclear receptor superfamily and consists of two major subtypes namely, ERa and ERb. The former is comprised of 595 residues and found on chromosome 6q while the latter is comprised of 530 residues and found on chromosome 14q. ERs have two major functional domains, the DNA-binding domain (DBD), which is responsible for DNA binding and dimerization, and the ligand-binding domain (LBD) that plays an important role in binding to different ligands and interacting with co-regulatory proteins. In addition, the N-terminus of ERs are highly viable and contain a transactivation domain, which interacts directly with other transcription factors. Furthermore, the C-terminus of the ERs are thought to affect the transactivation capacity of the receptors Fig. 1 . 6 Most ligands can bind to both types of ERs but differ in their binding affinities 7 due to the high similarity of the ERa and ERb in their DBD and a 55% similarly in their LBD. 8 In response to estrogen, ERa and ERb function as ligand-activated transcription factors that bind the estrogen response elements (EREs) and interact with co-activator or co-repressor proteins to regulate gene transcription. [9] [10] [11] [12] Aside from causing cancer, abnormal ER signaling may also give rise to cardiovascular, metabolic, inammatory and neurodegenerative diseases as well as osteoporosis. 13 Apart from the genomic effects, ERs are also known to exert extra-nuclear actions by which they regulate important cellular processes such as, leading cell proliferation, cell differentiation, and cell signaling to contributing to a biological outcome of tumor angiogenesis. 14, 15 Both ERa and ERb are crucial for regulating mammary growth and development. 16, 17 Under normal physiological conditions, ERa mediates the proliferative actions of E2 which can be opposed by ERb and together these receptors maintain a subtle balance of estrogen signalling in the cells. 18 ERa is normally expressed in only 10-20% of human mammary epithelial cells while 80-85% of cells express ERb. 19, 20 In contrast, the expression of ERa is increased while that of ERb is decreased in breast cancer cells. 19, 21 Therefore, the expression of ERa is used as a measure of steroid hormone receptor status and is currently an acceptable prognostic marker for predicting the response to hormonal therapy. 22 Unfortunately, the role of ERb in breast cancer is still not well understood. 23, 24 However, it has been postulated that increased protein levels of ERb are linked to a better prognosis, increased survival and a better response to anti-estrogen therapy.
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As previously mentioned, the expression of ERa is greatly increased in breast cancer cells and as such represents a promising therapeutic target for combating breast cancer. Anti-estrogens are agents that can hinder the production or utilization of estrogen and are categorized into two general classes: (i) selective estrogen receptor modulators (SERMs) and (ii) the so-called "pure" antagonists. The rst class or SERMs are drugs that competitively binds ERa and ERb and function by direct agonistic or antagonistic interactions. The outcome of such ER-binding is tissue-dependent meaning that some SERMs may exert agonistic response in one tissue and antagonistic response in another tissue. Tamoxifen represents a drug in the class of SERMs that serves as the rst line of treatment against breast cancer. It is currently being administered to patients in an effort to regress tumor growth of ER positive (ER+) breast cancers. The second class of anti-estrogens or "pure" antagonists (i.e. ICI 182780 also known as Fulvestrant/ Faslodex) works by preventing the binding of helix-12 to the surface of the ligand-binding domain, which in turn prevents the transcriptional activation of ERa. In spite of current endocrine therapies against estrogen, which represents a signicant advance in breast cancer therapy in which many women develop resistance to current drugs. The selection and outgrowth of breast cancers resistant to endocrine therapy is common and most deaths arising from breast cancer are found in patients with ERa+ tumors. 25 Moreover, in ERa+ breast cancers, onethird of women treated with tamoxifen for a period of 5 years will develop a recurrent disease within 15 years. Thus, the development of tamoxifen and aromatase inhibitor resistance remains a key problem in breast cancer treatment.
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Computational approaches have oen been used to complement experimental studies for several reasons, which among others include: (i) handle and manage large volumes of biological and chemical information, (ii) model biomolecular phenomenons that may be impossible by experimental means and (iii) making sense of data by uncovering hidden patterns and trends. In the context of drug discovery efforts, in silico approaches can be used to not only help identify and prioritize classes of compounds to screen but it can also help reduce the number of compounds to be tested. Quantitative structureactivity relationship (QSAR) is ligand-based approach in computational drug design for correlating the molecular features of a chemical library with their respective bioactivity. [26] [27] [28] QSAR has been instrumental in shedding light on the molecular basis of bioactivity of interest by learning from past bioactivity data while also being amenable to extrapolating on the bioactivity of new compounds that are foreign to the trained data set. The utilization of QSAR for the investigation of ERs had started in 1986 where Singh 29 examined the binding affinity of 2-phenylindoles towards estrogen receptor using Kiers rst-order valence molecular connectivity index. Thusfar, there exist 56 research articles reporting the QSAR modeling of ER inhibitors according to a search on Scopus for articles containing (QSAR or QSPR or "quantitative structure-activity relationship") and ("estrogen receptor" or ERa or ERb) as search query. A brief analysis of the existing QSAR models of ER revealed that nearly all are based on small data sets that are typically less than 50 compounds (i.e. belonging to the same congeneric class) while focusing on the selectivity of inhibitors against the two ER isoforms via classical QSAR [30] [31] [32] and 3D-QSAR. 33, 34 However, there were only a few studies reporting the use of large data set for the QSAR modeling of ER inhibitors. Among this are the work of Gao et al. 35 whose data set consisted of 463 compounds, the work of Mekenyan et al. 36 reporting a data set size of 151 compounds and the work by Fang et al. 37 on a set of 230 compounds.
This study explores the origin of ERa inhibitory activity by discerning their underlying structure-activity relationship via QSAR modeling. To achieve this, interpretable and simple to compute descriptors in concomitant with interpretable learning method were employed. The effectiveness and usefulness of twelve classes of ngerprint descriptors for model construction was determined. Molecular features important for the investigated ERa inhibitory activity were revealed via the Gini index and their contribution were to discerned in light of previous evidences from the literature. A schematic illustration of the QSAR modeling workow for predicting the inhibitory activity of ERa is provided in Fig. 2 .
Materials and methods

Data collection
A data set consisting of 5809 compounds with 10 936 bioactivity data points targeting human ERa (CHEMBL206) was obtained from the ChEMBL database, 38 version number 23. A subset of the data reporting IC 50 as the bioactivity value was selected for further investigation and this consisted of a total of 3641 compounds. Next, entries with < or > signs were subjected to removal as external data set while entries having CON-FIDENCE_SCORE equal to 9 (i.e. a direct single protein target is assigned) and those with ASSAY_TYPE equal to B (i.e. binding measurements of compounds to molecular targets as provided by K i , IC 50 and K D values) were selected for further use. Moreover, redundant compounds with (i) identical SMILES notation (ii) IC 50 value greater than 2 SD (i.e. if less than 2 SD then the median value is used) and (iii) missing IC 50 values were eliminated thereby further reducing the data set to 1780 compounds. Aer that, the SMILES notation for all entries from the data set was subjected to salt removal followed by its conversion to 2D structures using the Chem function of RDKit. 39 Finally, aer desalting the chemical structure, a set of 477 compounds having identical SMILES notation were removed. This resulted in the nal data set consisting of 1231 compounds. It is also worthy to note that IC 50 values were converted to pIC 50 units (Àlog IC 50 ) so as to afford a more uniform distribution of the data.
Descriptor calculation
Each compound was encoded by several sets of ngerprint descriptors computed using the PaDEL-Descriptor soware. 40 Briey, molecular ngerprint is a widely used molecular descriptor in cheminformatics owing to their ability to capture the feature space of chemical structures. However, the performance difference existing among these different ngerprint types has been the subject of several investigations on its utilization for bioactivity modeling. 41 Hence, this study considers 12 classes of molecular ngerprints consisting of AtomPairs 2D count, AtomPairs 2D, CDK ngerprinter, CDK extended, CDK graph only, E-state, Klekota-Roth count, Klekota-Roth, MACCS, PubChem, substructure count and substructure were used in this study. A summary of these descriptor types is provided in Table 1 . Briey, chemical structures stored in the MOL format were used as input for the calculation of ngerprints. For each compound, polar hydrogen atoms were added and tautomers were standardized prior to ngerprint calculation.
Data pre-processing
Prior to construction of the classication model, descriptors were subjected to mean centering and unit variance scaling as to afford comparability. Descriptors were removed if pairwise inter-correlation coefficients exceed the threshold value of 0.95 and correlation coefficient exceed the threshold value of 0.7. This resulted in reduced subsets consisting of 120, 154, 31, 951, 934, 599, 405, 452, 92, 196, 64 and 66 descriptors for AtomPairs 2D Count, AtomPairs 2D, CDK ngerprinter, CDK extended, CDK graph only, E-state, Klekota-Roth count, Klekota-Roth, MACCS, PubChem, substructure count and substructure, respectively, as summarized in Table 1 .
Data splitting
In the construction of prediction models, the possibility of bias may arise from a single data split. In order to address this problem, Puzyn et al. 48 suggested that prediction models should be constructed from N independent data splits. Thus, this study employs independent data splits using a split ratio of 70/30 where 70% of the entire data set was used as the internal set and the remaining 30% served as the external set. The nal prediction performance was obtained by calculating the mean and standard deviation values for statistical parameters from these independent data splits.
Multivariate analysis
Regression models afford the prediction of a continuous response variable (e.g. pIC 50 ) as a function of predictors (e.g. ngerprint descriptors) via the use of learning algorithms. Random forest (RF) is well-known as an ensemble machine learning technique that is capable of handling both classica-tion and regression tasks by making use of multiple decision tree learners to collectively predict the value of a target observation. 49 The RF model have been developed to improve the prediction performance of classication and regression trees (CART) by harnessing the power of several weak CART models.
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In the construction of a model, every CART is built from a xed number of randomly selected features for tree splitting while a bootstrap technique is used for sampling from the entire data set. RF boasts several advantages: (i) resilience toward overtting, (ii) provides built-in feature selection and (iii) relatively fast model building. RF models were constructed using the RandomForestClassier function from the scikit-learn machine learning library in Python. 51 Optimization of training parameters was performed programmatically by iteratively constructing regression models with each parameter adjustment.
Model assessment
One of the crucial processes in developing a QSAR model is the evaluation of the model's performance and robustness or validity of the model prior to its usage in predicting and interpreting the biological activities of compounds. Quantifying the condence and predictive accuracy of a model provides the decision-maker with the information necessary for establishing well-informed decisions. The squared value of Pearson's correlation coefficient (i.e. R Tr 2 and Q CV 2 for training and crossvalidated sets, respectively) and root mean squared error (RMSE) are two standard statistical parameters that are commonly used for evaluating the performance of QSAR models. This study employs 10-fold cross-validation (10-fold CV) to evaluate the model's performance in which a data set is partitioned into 10 data subsets aer which 9 subsets are used to train a model and subsequently evaluated on the held out subset (i.e. used as the test set). This procedure was repeated iteratively until all data subset had a chance to be held out as the test set while the remaining subsets were used as the training set for model building.
Aer construction of the RF model, a reduced subset of top 20 features were selected for the construction of the second RF model so as to avoid over-tting and to satisfy the philosophical Occam's razor principle in which a simple explanation is favorable to a more complicated one where analogously a model
Furthermore, external validation (Q Ext 2 ) was performed on the held out 30% external set. The reliability of QSAR models was provided by the difference of R 2 and Q 2 as originally proposed by Eriksson et al. 52 Further rigorous test for the possibility of chance correlation was performed via Yscrambling experiments in which the X-Y pairs are shuffled such that the resulting X-Y pairs are false pairs. If the resulting shuffled models afforded similar level of prediction performance with that of the original X-Y pair then it could be concluded that the model's performance is unreliable and arose by chance correlation. However, if the Y-shuffled models provided poor performance in comparison to the high performance of the original X-Y pair then it is indicative of the model's robustness. A total of 100 Y-scrambled models were computed.
Applicability domain analysis
The applicability domain of the QSAR model presented herein is assessed by means of the principal component analysis (PCA) bounding box approach. 53, 54 This essentially entails comparing the chemical space of compounds from the training set with those from the external set via PCA analysis of scores plot. This was performed using the PCA function from the sklearn.decomposition module from the scikit-learn machine learning library in Python.
Reproducible research
To afford the reproducibility of this research, the code and data used in the construction of QSAR models and analyses 
Results and discussions
The Organization for Economic Co-operation and Development (OECD) had dened a set of rules 55 for the development of robust QSAR models as follows: (i) dened endpoint, (ii) unambiguous algorithm, (iii) dened applicability domain, (iv) evaluation of the model's predictive potential and (v) mechanistic interpretation. These OECD principles were implemented herein as to ensure the robustness of constructed QSAR models.
Chemical space and applicability domain analysis
An exploration of the general chemical space of the investigated data set by means of Lipinski's rule-of-ve (Ro5) descriptors is provided in ESI Fig. 1 Fig. 2 . † Briey, the Ro5 describes the druglikeness of compounds on the basis of their molecular properties namely molecular weight (<500), octanol-water partition coefficient (log P; <5), the number of hydrogen bond acceptors (<10) and the number of hydrogen bond donors (>5). As useful as the Ro5 are, they have been shown to afford limited value in contributing to our understanding on the underlying principles of the target-ligand relationship (i.e. the affinity of the ligand toward the target) as they were strictly based on general molecular properties of the ligand. Oprea et al. 56 showed that the Ro5 criteria do not serve to discriminate drugs from nondrugs in which more than 90% of the compilation of chemical reagents known as the Available Chemicals Directory were also Ro5 compliant. However, this does not negate the notion that the criteria exemplied by the Ro5 cannot be used to narrow properties that are useful for therapeutically relevant pharmacokinetic space. Moreover, Benet et al. 57 has shown that QSAR model built using the Ro5 criteria could successfully predict drug disposition characteristics for drugs both meeting and not meeting the Ro5 criteria. Fig. 3 revealed that of the 1231 compounds present in the curated data set, roughly two-third of compounds had zero violation while the other one-third of compounds are distributed between one and two violations. In this latter set, approximately three-quarter fell in the one Ro5 violation spectrum with the remaining one-quarter falling within the two Ro5 violation zone. It is interesting to note that as the number of Ro5 violations increased, the bioactivity also increased (Fig. 4) .
A closer look revealed that a minority proportion of compounds in violation of the Ro5 was due to the fact that it had molecular weight greater than 500 Da. On the other hand, a larger proportion of compounds in violation of the Ro5 was because they had log P value greater than 5. In spite of this, it should be noted that Lipinski et al. 58 pointed out that compounds in violation of the Ro5 should not necessarily be removed from further consideration. In fact, efforts have been directed to soen the Ro5 59 as it is well known that there are several instances where therapeutically useful drugs are in violation of several Ro5 parameters such as Atorvastatin, Lipitor, Losartan, Montelukast, Olmesartan, Telaprevir, Telmisartan, etc. It is worthy to note that the Ro5 should be used sparingly as general guidelines and not as strict rules so as to set loose criteria that would allow the discovery of potent drug candidates that may at rst glance be removed if the Ro5 criteria was strictly followed.
The applicability domain of the QSAR model proposed herein was assessed via the PCA bounding box approach in which the chemical space spanned by the training set (i.e. the 70% subset) is compared to that of the external set (i.e. the 30% subset) as shown in Fig. 5 . It was found that the chemical space spanned by the external set falls within the boundaries of the chemical space of the training set and thus is also deemed to be within the applicability domain of the constructed QSAR model. Moreover, the relative chemical space spanned by compounds from internal and external sets as visualized in Fig. 6 can be seen to share a high degree of similarity as also seen from the PCA scores plot.
QSAR modeling
The curated data set comprising of 1231 compounds was used for the construction of QSAR models for predicting the ERa inhibitory activity of a structurally diverse compounds spanning several scaffolds. Molecular features of compounds were described by several ngerprint types. The intrapolation and generalization ability of QSAR models was examined on internal and external sets obtained from several rounds of data splits. Each of the twelve models were built using a data split ratio of 70/30 in which 70% of the data set was used as the internal set and 30% as the external set. The rst data subset consisting of 70% was used for internal validation of the QSAR model (i.e. used as the training set as well as the cross-validation set) and its performance was consequently evaluated by R 2 , Q 2 and RMSE. The second data subset containing 30% of the bioactivity data was utilized for external validation and their performance was assessed by Q 2 and RMSE.
Models were constructed via the RF algorithm and their results are presented in Table 2 . Assessment of the predictive performance of the model was performed according to the suggested statistical thresholds of Golbraikh and Tropsha 60, 61 in which acceptable models should have R 2 > 0.6 and Q 2 > 0.5.
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Results indicated that the two best models as judged from both internal and external validation, which consisted of AtomPairs to its interpretability and fewer number of descriptor (i.e. 307 descriptors as compared to 780 to 4860 descriptors from the other ngerprints), which also require less computation time.
The possibility for chance correlation can be assessed from the R 2 -Q 2 margin as described by Eriksson 52 where values <0.2-0.3 are indicative of predictive and reliable models while values >0.2-0.3 suggests possible chance correlation or the presence of outliers in the data set. Furthermore, from observation of the R Tr 2 À Q Ext 2 margin, it is revealed that differences were negligible with values not greater than 0.2. Fig. 7a and b shows the scatter plots of experimental versus predicted pIC 50 values. As for the threshold value for RMSE, which is rather difficult to establish, but generally models with higher RMSE values can be considered to afford sub-optimal prediction. Such high RMSE value may be due to the presence of a small number of outlying compounds that give rise to high error predictions. 62 Furthermore, the inherent variability of experimental assays in concomitant with the diversity of chemotypes present in the data set are also expected to directly give rise to prediction error. 
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Moreover, the proposed models were further subjected to stringent test to evaluate the possibility of chance correlation by carrying out Y-scrambling experiments. Briey, this encompassed the shuffling of the X block of descriptors with that of its corresponding Y label such that the shuffled data set have false X-Y pairs whereas the original data set had true X-Y pairs. Fig. 7b and c shows the results from the Y-scrambling experiment and it can be seen that original models (i.e. denoted by blue circles) for all ngerprint class are found to be located at the upper right quadrant thereby suggesting robust models in accordance with the threshold of Golbraikh and Tropsha.
60 On the other hand, Y-scrambled models (i.e. represented by red circles) were found to be lying within the boundaries of the lower le quadrant, which is indicative of their poor performance.
Additional external validation
To further evaluate the model performance, additional external sets consisting of qualitative bioactivity class labels (i.e. IC 50 values having < or > signs) were used. This external set was preprocessed in the same manner as that of the internal set and the aforementioned top 20 features were used as descriptors. The rst external set is comprised of 283 compounds with > sign in the bioactivity class label and the internal set was found to afford an accuracy of 0.88 for this external set (i.e. predicted values had higher value than the specied value in the bioactivity class label). In contrast, the second external set in which compounds having < sign in the bioactivity class label could produce a rather low accuracy of 0.16. A closer analysis revealed that compounds in the former external set were experimentally evaluated using bioactivity assay formats also found in the training set whereas the bioactivity assay formats for compounds in the second external set was not found in the respective training set. Thus, it could be rationalized that compounds in the rst external set (i.e. having > sign in the bioactivity class label) were in the applicability domain as those used to train the model whereas those in the second external set (i.e. having < sign in the bioactivity class label) were outside the applicability domain of the trained model owing to inherent differences in the assaying methods of the training set and that of this second external set as well as the fact that compounds in this set are less presented in the training set.
Mechanistic interpretation of important features
Important features that are important for the investigated bioactivity could be deduced from the constructed QSAR models by analyzing the Gini index. Fig. 8 ranks these important features by displaying the mean decrease of the Gini index. Table 3 lists the top-ranking substructure count descriptors along with their respective description.
As can be seen in Fig. 8 , the top ranking feature is phenol (SubFPC169), which contains a 1,2-benzenediol moiety and belongs to the class of organic compounds known as catechols. Catechols are secondary metabolites found in many plants that have been shown to confer numerous bioactivities.
The second top-ranked feature is the aromatic (SubFPC274) descriptor, which is a ubiquitous substructure that plays an important structural role as scaffolds of compounds as well as functional moieties that mediates p-p stacking interaction. Differences in the number and type of atoms in the aromatic rings of molecules can present various development concerns such as aqueous solubility, lipophilicity, serum albumin binding, cytochrome P450 inhibition and hERG inhibition.
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The third top-ranked feature is amine (SubFPC23) which present in amino acids are used to form bonds that are essential for their electron donation property. The bioavailability of a drug-like molecule is related to its rotatable bond (SubFPC302), the fourth important feature, number where drug-like compounds have 10 or fewer rotatable bonds. Although, this is not absolute as some effective inhibitors carry more than 12 rotatable bonds. 66 In recent years, many highly potent molecules carrying more than 10 rotatable bonds are still administered through the oral route with some modications to their dosage forms.
The h and sixth important features are amine (SubFPC88) and secondary carbon (SubFPC2), respectively. Carboxylic acid is a common functional group found in the pharmacophore of diverse classes of therapeutic agents. 67 Currently, a large number (>450) of carboxylic acid-containing drugs have been marketed worldwide. The secondary carbon, which is attached to two other carbons, is also a common component in the structure of some anti-cancer agents.
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The seventh and eighth important features are hetero N nonbasic (SubFPC181) and conjugated double bond (SubFPC287), respectively. Hetero N nonbasic can be dened as an aromatic nitrogen atom having two further total connections or an aromatic nitrogen atom affording a charge of +1 with three further total connections. Therefore both features are essential for anticancer activity in compound structure. 69, 70 In a conjugated double bond, the double bonds are separated by two or more methylene groups and can react with nucleophiles in a similar fashion as the aromatic ring (i.e. withdrawing electrons from electronegative atoms).
The ninth and tenth important substructures are vinylogous ester (SubFPC137) and alkyl aryl ether (SubFPC18), respectively. These two functional groups have been found in several breast cancer drugs. 71, 72 Alkyl aryl ether is also a key substructure of Tamoxifen, which is a selective estrogen receptor modulator as well being one of the oldest and most-prescribed FDA-approved drug for hormonal therapy. Tertiary aliphatic amine SubFPC88
Carboxylic acid derivative SubFPC302 Rotatable bond Fig. 9 Binding pocket of the ligand-binding domain of ERa in complex with CHEMBL304552 (PDB id: 1SJ0). Helices and sheets are depicted in gray color, the ligand is represented in orange colored sticks while its interacting residues are colored blue. Important interactions are indicated by colored dashed lines as follows: brown, hydrophobic interactions; yellow, salt bridge; green, p-stacking interaction (parallel).
Structural analysis of important features
A large set of 240 crystal structures of human ERa ligandbinding domain was retrieved from RCSB Protein Data Bank. An analysis of the active site of these structures revealed that most afforded hydrogen bonding to Arg394, His524 and Glu353. A closer observation of the ligand-binding domain of ERa (PDB id: 1SJ0) as shown in Fig. 9 revealed that Glu353 and Arg394 are engaged in hydrogen bonding with the oxygen atom from the ligand's phenol moiety. Important features as obtained from the QSAR model corroborate the aforementioned molecular interaction. Particularly, this includes phenol (SubFPC169), C-ONS bond (SubFPC295) and carboxylic acid derivative (SubFPC88). Moreover, p-p interaction with Phe336 were also found to be prevalent amongst the molecular interaction with ligands. This is well supported by the aromatic (SubFPC274) descriptor from the QSAR model.
Conclusion
Molecular ngerprints is a robust descriptor type with immense utility in cheminformatics and computer-aided drug design owing to its information-rich description on the structural details of investigated compounds. The advantage of these descriptors is that they can be rapidly generated in a highthroughput fashion while also affording robust performance and interpretability. In this work, we elucidate the origin of ERa inhibitory activity via QSAR models based on molecular ngerprints. In this study, we performed a comparative evaluation of the classication performance afforded by twelve ngerprint types using the ensemble learning approach based on random forest. Important features contributing to ERa inhibitory activity were deduced from the Gini index of topranking substructure ngerprints. It was found that 1,2-diphenol, primary aliphatic amine, quaternary aliphatic ammonium, carbothioic acid, acyliodide, diaryl ether bond, tertiary carbon, vinylogous amide, conjugated triple bond and nitrite were important substructures for the observed ERa inhibitory activity. Thus, the QSAR model proposed herein has great utility as a high-throughput platform that can be used to screen large chemical libraries for identifying promising hit compounds for further experimental validation. Moreover, the molecular insights gained are also useful as guidelines for the design of robust ERa inhibitors.
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